MX2020005481A - Purificacion de saponina. - Google Patents

Purificacion de saponina.

Info

Publication number
MX2020005481A
MX2020005481A MX2020005481A MX2020005481A MX2020005481A MX 2020005481 A MX2020005481 A MX 2020005481A MX 2020005481 A MX2020005481 A MX 2020005481A MX 2020005481 A MX2020005481 A MX 2020005481A MX 2020005481 A MX2020005481 A MX 2020005481A
Authority
MX
Mexico
Prior art keywords
saponin
saponin purification
purification
extracts
absorbance
Prior art date
Application number
MX2020005481A
Other languages
English (en)
Inventor
Ahmad Taimour Baig
Garcia Juan Jose Diaz
Chad Austin Farrenburg
Kent Raymond Myers
Jeri Kay Sandvick
Jeb Yeatts Vandenburg
Felicie Georgette Colette Denet
Lora Lea Lawrence
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of MX2020005481A publication Critical patent/MX2020005481A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Extractos de saponina que contienen al menos 93% de pico principal QS-21 y 0.25-3% de componente 2018 por absorbancia UV a 214 nm, métodos para elaborar dichos extractos, su uso como adyuvantes de vacunas y aspectos relacionados.
MX2020005481A 2017-12-01 2018-11-30 Purificacion de saponina. MX2020005481A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762593581P 2017-12-01 2017-12-01
EP17209780 2017-12-21
PCT/EP2018/083234 WO2019106192A1 (en) 2017-12-01 2018-11-30 Saponin purification

Publications (1)

Publication Number Publication Date
MX2020005481A true MX2020005481A (es) 2020-12-07

Family

ID=64661325

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005481A MX2020005481A (es) 2017-12-01 2018-11-30 Purificacion de saponina.

Country Status (9)

Country Link
US (2) US11591364B2 (es)
EP (1) EP3717001A1 (es)
JP (2) JP2021504424A (es)
CN (1) CN111670044A (es)
BR (1) BR112020010790A2 (es)
CA (1) CA3083078A1 (es)
CL (1) CL2020001440A1 (es)
MX (1) MX2020005481A (es)
WO (1) WO2019106192A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021504429A (ja) 2017-12-01 2021-02-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン抽出
BR112020010790A2 (pt) * 2017-12-01 2020-11-10 Glaxosmithkline Biologicals S.A. purificação da saponina
JP7640473B2 (ja) * 2019-06-05 2025-03-05 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
KR20230013237A (ko) 2020-03-09 2023-01-26 다이나박스 테크놀로지 코퍼레이션 Tlr9 효능제를 포함하는 대상포진 백신
US20230277657A1 (en) 2020-05-05 2023-09-07 Glaxosmithkline Biologicals Sa Microfluidic mixing device and methods of use
AU2021321944A1 (en) 2020-08-07 2023-04-06 Access To Advanced Health Institute Purified saponins and chromatographic process for purification of same
IL302397A (en) 2020-10-28 2023-06-01 Sanofi Pasteur Liposomes containing a TLR4 agonist, their preparation and uses
WO2023020994A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020992A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020993A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
JP2024538802A (ja) 2021-10-19 2024-10-23 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニンの生成
CN119912535A (zh) * 2021-12-28 2025-05-02 成都迈科康生物科技有限公司 一种hpv抗原及其相关产品
CN114703205A (zh) * 2022-03-11 2022-07-05 上海博唯生物科技有限公司 一种疱疹病毒糖蛋白gE重组蛋白、疫苗、制备方法和应用
WO2024145204A1 (en) * 2022-12-29 2024-07-04 Q-Vant Biosciences, Inc. Modified qs-21 compositions and processes for producing the same and uses therefor
WO2024261351A2 (en) 2024-05-08 2024-12-26 Vaccine Formulation Institute Ch Ltd. Immunologically active saponin fractions and adjuvant formulations

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4769239A (en) 1984-08-21 1988-09-06 Merck & Co., Inc. Vaccine against varicella-zoster virus
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5173294A (en) 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
JP2733263B2 (ja) 1988-10-04 1998-03-30 キヤノン株式会社 集積型光ノードおよびそれを用いたバス型光情報システム
EP0405867B1 (en) 1989-06-27 1995-03-15 SMITHKLINE BEECHAM BIOLOGICALS s.a. Novel compounds
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
ATE177755T1 (de) 1991-11-16 1999-04-15 Smithkline Beecham Biolog Hybrides protein zwischen cs aus plasmodium und hbsag
US6169171B1 (en) 1992-02-27 2001-01-02 Smithkline Beecham Biologicals (S.A.) Hybrid protein between CS from plasmodium and HBSAG
US5928902A (en) 1992-02-27 1999-07-27 Smithkline Beecham Biologicals (S.A.) Hybrid protein between CS from plasmodium and HBsAg
GB9224584D0 (en) 1992-11-23 1993-01-13 Connaught Lab Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases
ES2185658T3 (es) 1993-05-18 2003-05-01 Univ Ohio State Res Found Vacuna para la otitis media.
KR0184779B1 (ko) 1995-04-13 1999-04-01 성재갑 퀼라야 사포나리아 몰리나로부터 분리정제된 사포닌 변이체, 이의 분리정제 방법 및 이를 함유하는 백신 제형
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
GB9513074D0 (en) 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US6090576A (en) 1996-03-08 2000-07-18 Connaught Laboratories Limited DNA encoding a transferrin receptor of Moraxella
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
FR2748748B1 (fr) 1996-05-17 1998-11-06 Pasteur Institut Identification et clonage d'un antigene mycobacterien correspondant a une hemagglutine de liaison a l'heparine
GB9616351D0 (en) 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
DE69637435T2 (de) 1996-12-02 2009-02-19 Antigenics Inc. Saponin-zusammensetzungen und deren verwendung
US6231859B1 (en) * 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
CA2292838A1 (en) 1997-06-03 1998-12-10 Connaught Laboratories Limited Lactoferrin receptor genes of moraxella
AU3589899A (en) * 1998-04-17 1999-11-08 Her Majesty The Queen In Right Of Canada As Represented By The Department Of Agriculture And Agri-Food Canada Process for recovery and purification of saponins and sapogenins from quinoa ((chenopodium quinoa))
GB9812613D0 (en) 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
FR2832410B1 (fr) 2001-11-19 2004-04-02 Pasteur Institut Antigene mycobacterien recombinant de type hemagglutinine de liaison a l'heparine methylee, procedes de preparation et compositions immunogenes comprenant un tel antigene
PL1697403T3 (pl) 2003-12-23 2010-09-30 Nationwide Childrens Hospital Inc Pilusy typu IV Haemophilus influenzae
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
AU2007206114B2 (en) 2006-01-17 2013-01-24 Arne Forsgren A novel surface exposed Haemophilus influenzae protein (protein E; pE)
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PT2468300T (pt) 2006-09-26 2018-01-30 Infectious Disease Res Inst Composição para vacina contendo adjuvante sintético
HRP20161606T1 (hr) 2007-03-02 2017-01-13 Glaxosmithkline Biologicals Sa Novi postupak i pripravci
PL2222710T3 (pl) 2007-12-24 2017-01-31 Id Biomedical Corporation Of Quebec Rekombinowane antygeny rsv
PT2315773T (pt) 2008-07-25 2016-11-23 Glaxosmithkline Biologicals Sa Polipéptidos, polinucleótidos e composições para utilização no tratamento de tuberculose latente
MX2011000982A (es) 2008-07-25 2011-03-02 Glaxosmithkline Biolog Sa La proteina de tuberculosis rv2386c, composiciones y usos de la misma.
HUE037121T2 (hu) 2008-07-25 2018-08-28 Glaxosmithkline Biologicals Sa Új készítmények és eljárások
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
US20130018178A1 (en) 2009-06-22 2013-01-17 Px Therapeutics Method for the purification of hbha
MX2012000035A (es) 2009-06-24 2012-02-28 Id Biomedical Corp Quebec Antigenos de virus de sincicio respiratorio recombinantes.
EP4218799A1 (en) 2009-07-15 2023-08-02 GlaxoSmithKline Biologicals S.A. Rsv f protein compositions and methods for making same
SI2528621T1 (sl) 2010-01-27 2017-01-31 Glaxosmithkline Biologicals S.A., Modificirani tuberkolozni antigeni
PL2651436T3 (pl) 2010-12-14 2016-10-31 Kompozycja antygenów mykobakteryjnych
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
DK2707385T3 (da) 2011-05-13 2017-11-20 Glaxosmithkline Biologicals Sa RSV-F-præfusionsantigener
GB201213364D0 (en) 2012-07-27 2012-09-12 Glaxosmithkline Biolog Sa Purification process
US20140141037A1 (en) 2012-11-20 2014-05-22 Novartis Ag Rsv f prefusion trimers
FI2970398T3 (fi) 2013-03-13 2024-08-06 Us Health Rsv f -prefuusioproteiineja ja niiden käyttö
GB201316463D0 (en) 2013-09-16 2013-10-30 Giles Clark & Cook Ltd Novel compositions
TW201620927A (zh) 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Ｕｓｐａ２蛋白質構築體及其用途
GB201405921D0 (en) 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
EP3662440B1 (en) 2017-08-04 2021-12-29 Ventana Medical Systems, Inc. Color unmixing with scatter correction
WO2019047150A1 (en) 2017-09-08 2019-03-14 The Procter & Gamble Company SIDE STOP PISTON VALVE ASSEMBLY
BR112020010790A2 (pt) 2017-12-01 2020-11-10 Glaxosmithkline Biologicals S.A. purificação da saponina
JP2021504429A (ja) 2017-12-01 2021-02-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン抽出

Also Published As

Publication number Publication date
US11591364B2 (en) 2023-02-28
CA3083078A1 (en) 2019-06-06
JP2024001012A (ja) 2024-01-09
WO2019106192A1 (en) 2019-06-06
EP3717001A1 (en) 2020-10-07
US20230272000A1 (en) 2023-08-31
JP2021504424A (ja) 2021-02-15
US12227540B2 (en) 2025-02-18
CN111670044A (zh) 2020-09-15
US20200317719A1 (en) 2020-10-08
CL2020001440A1 (es) 2021-02-19
BR112020010790A2 (pt) 2020-11-10

Similar Documents

Publication Publication Date Title
MX2020005481A (es) Purificacion de saponina.
CL2023000198A1 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
NZ725480A (en) Anti-ptk7 antibody-drug conjugates
AU366476S (en) Bottle
AU2016261707A8 (en) Use of cannabis to treat fibromyalgia, methods and compositions thereof
EP4193993A3 (en) Combinations of cannabinoids and n-acylethanolamines
EP4289820A3 (en) Compounds for use in treating alzheimer's disease in apoe4+/+ patients
MY191539A (en) Streptococcal vaccine
SA519401227B1 (ar) لقاح النيسرية السحائية
ZA201803476B (en) Anti-cd22 antibody-maytansine conjugates and methods of use thereof
ZA201701000B (en) Attenuated bovine coronavirus and related vaccines
EA201692154A1 (ru) Перорально распадающаяся пленка
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
MX365411B (es) Métodos para reducir el mal olor y las bacterias.
MX371128B (es) Compuestos de dihidropirimidin-2-ona y su uso medico.
NZ747261A (en) Stevia-containing beverage
MX2016009445A (es) Composicion de aminas con olor enmascarado.
MX2019013250A (es) 2,3,7-trimetiloct-6-enil acetato y 3,7-dimetil-2-metilen-oct-6-eni l acetato y derivados de estos y su uso como sustancias quimicas aromaticas.
MX391147B (es) Composiciones para diferenciación y proliferación celular que comprenden la combinación de un extracto de acmella oleracea (espilantol) con extracto de camellia sinensis.
EP4505880A3 (en) Stevia extracts
BR112017019154A2 (pt) uso de frações isoladas de goma mástica para o tratamento de neuropatia óptica
MX395174B (es) Composiciones de triptamina y metodos de uso.
GB2560853A (en) Phytochemical recovery from plants
MX2017008655A (es) Derivados de jasmonato y composiciones de los mismos.
GB2583234B (en) Compositions including pine bark extract, berryfruit extract and a source of l-theanine and uses thereof